Study Comparing Casdatifan and Cabozantinib with Placebo and Cabozantinib for Advanced Kidney Cancer

Inclusion Criteria

• Have advanced kidney cancer that cannot be removed by surgery and can be measured by scans.
• Have a Karnofsky Performance Status (KPS) score of 80% or higher, indicating good overall health.
• Have at least one tumor that can be measured by CT or MRI scans and is not in an area that has been treated with radiation.
• Have good organ and bone marrow function as shown by tests done within 72 hours before starting the study.
• Women who can become pregnant must have a negative pregnancy test before joining the study.

Exclusion Criteria

• Have previously been treated with a HIF-2α inhibitor or cabozantinib.
• Have had another active cancer within the past year, except for certain types that have been successfully treated.
• Have severe side effects from previous cancer treatments, or side effects that are Grade 3 or higher according to medical guidelines.
• Have high blood pressure that is not well controlled, even with more than three medications.
• Have a history of cancer spreading to the brain or spinal cord.